Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

Social media influencer Kusha Kapila says she takes a shot of fresh onion juice to instantly relieve stomachache. Kusha, in ...

Getting regular exercise before a cancer diagnosis may slow progression of the disease, a new study finds.Researchers say even relatively low levels of exercise ...

Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage ...

Researchers at The Clatterbridge Cancer Centre NHS Foundation Trust are using AI to enhance the precision of radiotherapy for ...

Our health is our greatest asset and taking a proactive approach can prevent small issues from becoming big problems. Whether ...

Janux Therapeutics has a robust balance sheet, with $658.1 million in liquid assets and no debt. See why I reiterate my buy ...

In one analysis, 16% of men with no suspicious lesions on MRI had clinically significant prostate cancer identified after ...

Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours: San Diego, California Wednesday, ...

An ultrasound test that takes less than 20 minutes could improve the accuracy of prostate cancer diagnosis, scientists say.

Investing.com -- Shares of Vir Biotechnology, Inc. (NASDAQ: VIR) surged 29% following the release of encouraging safety and efficacy data from ongoing dose escalation trials for its dual-masked T-cell ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...